Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference

Rhea-AI Summary

Horizon Therapeutics (HZNP) will present new data on Thyroid Eye Disease (TED) at the Endocrine Society’s Annual Conference (ENDO 2022) from June 11-14 in Atlanta. Key presentations include the efficacy of Teprotumumab and its impact on blood glucose in TED patients. Gail Devers, a three-time Olympic gold medalist living with Graves' disease and TED, will discuss her journey and advocate for early symptom recognition. Horizon will also host a product theater on TED treatment advancements. These efforts emphasize the company's commitment to addressing unmet needs in rare autoimmune diseases.

Positive

• Presentation of Phase 2 and Phase 3 trial results on blood glucose levels in TED patients.
• Increased awareness and advocacy for TED treatment, highlighted by Gail Devers' participation.
• Focus on the efficacy of Teprotumumab for TED, potentially improving patient outcomes.

Negative

• None.

-- Poster presentation will share results from the Phase 2 and Phase 3 trials on blood glucose levels in patients with Thyroid Eye Disease (TED) --

-- Three-time Olympic gold medalist Gail Devers will discuss her experience living with Graves’ disease and TED at events on Saturday, June 11 and Sunday, June 12 --

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the Endocrine Society’s Annual Conference (ENDO 2022) in Atlanta, June 11-14, including:

• Title: Use of Steroids Pre- and Post-Teprotumumab in Thyroid Eye Disease Patients
  • Session: Poster Hall A1 PSAT261, RJ Holt​
  • Date: Saturday, June 11, 1-3 p.m. ET

• Title: Blood Glucose in Thyroid Eye Disease (TED) in Patients Treated with Teprotumumab: Clinical Trials Data
  • Session: Poster Hall A1 PSAT265, TJ Smith
  • Date: Saturday, June 11, 1-3 p.m. ET

• Title: Efficacy of Teprotumumab for Thyroid Eye Disease in Hyper- and Hypothyroid Patients
  • Session: Poster Hall A1 PSAT389, TJ Smith​
  • Date: Saturday, June 11, 1-3 p.m. ET

• Title: Teprotumumab Markedly Improves Disease-Related Quality of Life: Lessons From Two Randomized, Placebo-Controlled Trials
  • Session: Oral Presentation OR11, GJ ​Kahaly
  • Date: Sunday, June 12, 11:30 a.m. - 1 p.m. ET
    
    

Horizon will host a product theater on Saturday, June 11 at 1 p.m. ET in ENDOExpo Theater 1, titled “Evolution of Thyroid Eye Disease (TED) Treatment With Teprotumumab: Translating Bench to Bedside” with Terry J. Smith, M.D., Michigan Medicine Eye Plastic, Facial Cosmetic & Orbital Surgery, Kellogg Eye Center, University of Michigan Medical School.

Additionally, Olympian Gail Devers, who lives with Graves’ disease and TED, will join Eve D. Bloomgarden, M.D., Director of Thyroid Care and Endocrine Innovation and Education for the Division of Endocrinology at NorthShore University Health System, for a discussion on Gail’s journey to a TED diagnosis and how endocrinologists can identify symptoms early and consult with a TED eye specialist. The event, “Achieving Gold in the Co-Management of Thyroid Eye Disease (TED),” will be held in The Career and Communications Center in the Exhibit Hall on Saturday, June 11 at 11 a.m. ET.

Gail will also be sharing her story between 11 a.m. and 4 p.m. ET at Horizon’s Listen to Your Eyes Mobile Exhibit on Sunday, June 12. It will be open from 10 a.m. until 5 p.m. ET at Atlantic Station. Those living with TED or Graves’ disease are invited to visit the exhibit to meet Gail, learn about TED and connect with others who have shared experiences. Register here.

About Gail Devers

Gail Devers is a world-renowned track star and three-time Olympic gold medalist who has been living with Graves’ disease and symptoms of TED for more than 30 years. After a harrowing two-and-a-half-year quest for answers, she was diagnosed with Graves’ disease in 1990, just two years before winning her first Olympic gold medal. Her journey back to the track was nothing short of remarkable as she suffered near career-ending symptoms, including extreme weight loss, fatigue and insomnia. She also had symptoms of TED including eye pain, dryness, irritation and bulging eyes. In her decorated 25-year track career that followed, Gail has been recognized as a five-time Olympian, back-to-back 100m Olympic champion, three-time 100m hurdles world champion, and inductee of both the National Track and Field and the United States Olympic Halls of Fame.

About Thyroid Eye Disease (TED)

TED is a serious, progressive and potentially vision-threatening rare autoimmune disease.¹ TED often occurs in people living with Graves’ disease, but is a distinct disease that is caused by autoantibodies activating an IGF-1R-mediated signaling complex on cells within the retro-orbital space.^2,3 This leads to a cascade of negative effects, which may cause long-term, irreversible damage. TED begins with an acute (active) phase where inflammatory signs and symptoms, such as eye pain, swelling, proptosis (eye bulging) and diplopia (double vision), progress over time.^1,4 The disease then enters a chronic phase where inflammation is no longer present or has markedly diminished, but significant signs and symptoms may remain. As TED progresses, the serious damage it can cause includes proptosis (eye bulging), strabismus (misalignment of the eyes) and diplopia (double vision) – and in some cases can lead to blindness.^4,5

About Horizon

Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

References

1. Barrio-Barrio J, et al. Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. Journal of Ophthalmopathy. 2015;2015:249125.
2. Weightman DR, et al. Autoantibodies to IGF-1 Binding Sites in Thyroid Associated Ophthalmopathy. Autoimmunity. 1993;16(4):251–257.
3. Pritchard J, et al. Immunoglobulin Activation of T Cell Chemoattractant Expression in Fibroblasts from Patients with Graves’ Disease Is Mediated Through the Insulin-Like Growth Factor 1 Receptor Pathway. J Immunol. 2003;170:6348-6354.
4. Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ Orbitopathy (EUGOGO) Clinical Practice Guidelines for the Medical Management of Graves’ Orbitopathy [published online ahead of print]. Eur J Endocrinol. 2021 Jul 1:EJE-21-0479.R1. doi: 10.1530/EJE-21-0479.
5. McKeag D, et al. Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. Br J Ophthalmol. 2007;91:455-458.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220601006252/en/

Investors:

Tina Ventura

Senior Vice President, Investor Relations

Investor-relations@horizontherapeutics.com

U.S. Media:

Rachel Vann

Director, Product Communications

media@horizontherapeutics.com

Ireland Media:

Gordon MRM

Ray Gordon

ray@gordonmrm.ie

Source: Horizon Therapeutics plc

FAQ

What data will Horizon Therapeutics present at ENDO 2022 related to Thyroid Eye Disease (HZNP)?

Horizon will present data on the efficacy of Teprotumumab and its impact on blood glucose levels in TED patients.

When is the Endocrine Society’s Annual Conference where Horizon will present its findings (HZNP)?

The conference will take place from June 11-14, 2022, in Atlanta.

Who is Gail Devers and what is her relevance to Horizon's presentation (HZNP)?

Gail Devers is a three-time Olympic gold medalist living with Graves' disease and TED, who will share her experience to raise awareness.

What will be discussed during Horizon's product theater at ENDO 2022 (HZNP)?

The product theater will focus on the evolution of TED treatment with Teprotumumab.